Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir

Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)

(2012) Fiona McPhee et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Single- and Multiple-Ascending-Dose Studies of the NS3 Protease Inhibitor Asunaprevir in Subjects with or without Chronic Hepatitis C

(2012) Claudio Pasquinelli et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Resistance Analysis of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir

(2012) Fiona McPhee et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: A randomized phase II study

(2012) Michael P. Manns et al.   HEPATOLOGY

Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5a replication complex inhibitor, BMS-790052

(2012) Jin-Hua Sun et al.   HEPATOLOGY

1096 ASUNAPREVIR (ASV; BMS-650032), AN NS3 PROTEASE INHIBITOR, IN COMBINATION WITH PEGINTERFERON AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION

(2012) J.-P. Bronowicki et al.   JOURNAL OF HEPATOLOGY

1215 PERSISTENCE OF NS5A GS-5885 DRUG RESISTANCE MUTATIONS FOLLOWING 3 DAYS OF MONOTHERAPY IN GENOTYPE-1 HCV PATIENTS IS DEPENDENT ON THE HCV SUBTYPE AND SPECIFIC MUTATION

(2012) K.A. Wong et al.   JOURNAL OF HEPATOLOGY

9 TMC435 IN PATIENTS INFECTED WITH HCV GENOTYPE 1 WHO HAVE FAILED PREVIOUS PEGYLATED INTERFERON/RIBAVIRIN TREATMENT: VIROLOGIC ANALYSES OF THE ASPIRE TRIAL

(2012) O. Lenz et al.   JOURNAL OF HEPATOLOGY

1172 ANTIVIRAL ACTIVITY AND RESISTANCE PROFILE OF THE NOVEL HCV NS5A INHIBITOR GS-5885

(2012) G. Cheng et al.   JOURNAL OF HEPATOLOGY

Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir

(2012) Yoshiyasu Karino et al.   JOURNAL OF HEPATOLOGY

Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options

(2012) Yoshiyuki Suzuki et al.   JOURNAL OF HEPATOLOGY

Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial

(2012) Stanislas Pol et al.   LANCET INFECTIOUS DISEASES

Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1

(2012) Anna S. Lok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Development of a chimeric replicon system for phenotypic analysis of NS3 protease sequences from HCV clinical isolates

(2011) Amy K Sheaffer et al.   ANTIVIRAL THERAPY

Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in Humans: In Vitro and In Vivo Correlations

(2011) Robert A. Fridell et al.   HEPATOLOGY

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders

(2011) Kazuaki Chayama et al.   HEPATOLOGY

1195 BMS-650032, AN NS3 INHIBITOR, IN COMBINATION WITH PEGINTERFERON ALPHA-2A AND RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION

(2011) J.-P. Bronowicki et al.   JOURNAL OF HEPATOLOGY

Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection

(2011) Bruce R. Bacon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telaprevir for Retreatment of HCV Infection

(2011) Stefan Zeuzem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an In Vitro Replicon System

(2010) R. A. Fridell et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

(2010) Min Gao et al.   NATURE